Back to Search Start Over

11-year experience with Chest Wall resection and reconstruction for primary Chest Wall sarcomas

Authors :
Ori Wald
Idais Islam
Korach Amit
Rudis Ehud
Erez Eldad
Or Omer
Zik Aviad
Shapira Oz. Moshe
Izhar Uzi
Source :
Journal of Cardiothoracic Surgery, Vol 15, Iss 1, Pp 1-7 (2020)
Publication Year :
2020
Publisher :
BMC, 2020.

Abstract

Abstract Background & Objectives Primary chest wall sarcomas are rare and therapeutically challenging tumors. Herein we report the outcomes of a surgery-based multimodality therapy for these pathologies over an 11-year period. In addition, we present a case that illustrates the surgical challenges that extensive chest wall resection may pose. Methods Using the Society of Thoracic Surgeons general thoracic surgery database, we have prospectively collected data in our institute on all patients undergoing chest wall resection and reconstruction for primary chest wall sarcomas between June 2008–October 2019. Results We performed 28 surgical procedures on 25 patients aged 5 to 91 years (median age 33). Eleven tumors were bone- and cartilage-derived and 14 tumors originated from soft tissue elements. Seven patients (7/25, 28%) received neo-adjuvant therapy and 14 patients (14/25, 56%) received adjuvant therapy. The median number of ribs that were resected was 2.5 (range 0 to 6). In 18/28 (64%) of surgeries, additional skeletal or visceral organs were removed, including: diaphragm [1], scapula [2], sternum [2], lung [2], vertebra [1], clavicle [1] and colon [1]. Chest wall reconstruction was deemed necessary in 16/28 (57%) of cases, polytetrafluoroethylene (PTFE) Gore-Tex patches was used in 13/28 (46%) of cases and biological flaps where used in 4/28 (14%) of cases. R0, R1 and R2 resection margins were achieved in 19/28 (68%), 9/28 (32%) and 0/28 (0%) of cases, respectively. The median follow up time was 33 months (range 2 to 138). During the study period, disease recurred in 8/25 (32%) of patients. Of these, 3 were re-operated on and are free of disease. At date of last follow up, 5/25 (20%) of patients have died due to their disease and in contrast, 20/25 (80%) were alive with no evidence of disease. Conclusions Surgery-based multimodality therapy is an effective treatment approach for primary chest wall sarcomas. Resection of additional skeletal or visceral organs and reconstruction with synthetic and/or biological flaps is often required in order to obtain R0 resection margins. Ultimately, long-term survival in this clinical scenario is an achievable goal.

Details

Language :
English
ISSN :
17498090
Volume :
15
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal of Cardiothoracic Surgery
Publication Type :
Academic Journal
Accession number :
edsdoj.8ceab510c27642d5882859867c5c8fef
Document Type :
article
Full Text :
https://doi.org/10.1186/s13019-020-1064-y